Drug intelligence / Profile preview

balhimycin

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Antimicrobial Peptides → Native Peptides → Peptides

Overview

Balhimycin is a novel glycopeptide antibiotic produced by the actinomycete Amycolatopsis balhimycina. It is structurally and mechanistically similar to vancomycin. Balhimycin acts by binding to the terminal Lys-D-Ala-D-Ala moiety of peptidoglycan precursors in bacterial cell walls, thereby inhibiting cell wall synthesis and leading to bacterial cell death. Its primary activity is against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The compound was first isolated from a soil sample collected in the Himalayas and has been studied for its unique sugar moieties and biosynthetic pathway[1][2][4][7].

Other names: balhimycin

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on balhimycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on balhimycin.

Explore the full profile